Company intelligence / Profile preview

Jurox

Rutherford, New South Wales, Australiajurox.com.au ↗

Ownership: Private
Development stage: Other

Overview

Jurox has a commercial-stage portfolio of more than 150 proprietary animal health products distributed globally. Its flagship product, Alfaxan® (alfaxalone), is a leading injectable anaesthetic for companion animals. The company also markets parasiticides, anti-infectives, cardiology drugs, and reproductive management solutions for both companion and production animals. Clinical results are consistent with regulatory approvals across multiple regions.

Therapeutic areas: EndocrinologyCardiovascularInfectious DiseasesOther
Modalities: Small moleculeBiologicVaccine
Industry: Veterinary

Partnerships

Now part of Zoetis global network; no major external partnerships disclosed post-acquisition.

Beyond the preview

Go deeper on Jurox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jurox.